Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Article in English | MEDLINE | ID: mdl-38556212

ABSTRACT

OBJECTIVES: We aimed to describe features and outcomes of cryptococcosis among HIV-seronegative individuals in a large surveillance network for cryptococcosis in France. METHODS: We included incident cases of cryptococcosis in HIV-seronegative individuals from 2005 to 2020. We compared patient characteristics, disease presentations, cryptococcal antigen results, and induction antifungal treatments according to underlying disease. We examined factors associated with 90-day mortality. Among patients with disseminated infections, we investigated whether receipt of flucytosine and polyene combination was associated with lower mortality. RESULTS: Among 652 individuals, 209 (32.1%) had malignancy, 130 (19.9%) were solid-organ transplant recipients, 204 (31.3%) had other immunocompromising conditions, and 109 (16.7%) had no reported underlying factor. The commonest presentations were disseminated infections (63.3%, 413/652) and isolated pulmonary infections (25.3%, 165/652). Solid-organ transplant patients were most likely to have disseminated infections and a positive serum cryptococcal antigen result. Patients with malignancy were older and less likely to receive a flucytosine-containing regimen for disseminated infections than others (58.7%, 78/133 vs. 73.2%, 194/265; p 0.029). The crude 90-day case-fatality ratio was 27.2% (95% CI, 23.5%-31.1%). Age ≥60 years (aOR: 2.75 [1.78-4.26]; p < 0.001), meningitis/fungaemia (aOR: 4.79 [1.80-12.7]; p 0.002), and malignancy (aOR: 2.4 [1.14-5.07]; p 0.02) were associated with higher 90-day mortality. Receipt of flucytosine and polyene combination was associated with lower 90-day mortality (aOR: 0.40 [0.23-0.71]; p 0.002) in multivariable analysis and inverse probability of treatment weighted analysis (aOR: 0.45 [0.25-0.80]; p 0.006). DISCUSSION: HIV-seronegative individuals with cryptococcosis comprise a wide range of underlying conditions with different presentations and outcomes, requiring a tailored approach to diagnosis and management.

3.
Pathogens ; 12(10)2023 Sep 29.
Article in English | MEDLINE | ID: mdl-37887721

ABSTRACT

Diagnosing neurocysticercosis (NCC) is difficult due to its variable clinical presentations and the different imaging techniques used to detect brain damage. This study aimed to evaluate the use of cerebrospinal fluid serology and PCR for diagnosing biological neurocysticercosis in a non-endemic country. We tested samples from patients living in France with suspected NCC and confirmed that 45 of the patients presented with the disease. A total of 89% of patients had previously traveled to countries where the disease was endemic. The sensitivity of Western blots compared to ELISA was not significantly different (80% vs. 60%) (p > 0.05), and neither was the sensitivity of Western blots vs. PCR (78% vs. 56%) (p > 0.05). The PCR sensitivity was 78% and 47% in definitive NCC and in probable NCC. PCR tests using cerebrospinal fluid should be considered as a diagnostic criterion for identifying NCC.

4.
Emerg Microbes Infect ; 12(2): 2258997, 2023 12.
Article in English | MEDLINE | ID: mdl-37706342

ABSTRACT

Intestinal microsporidiosis is most often caused by Enterocytozoon bieneusi, and to a lesser extent by species of the genus Encephalitozoon. Until now, Encephalitozoon hellem was not clearly known to induce disease restricted to the intestine, or rarely in HIV subjects or in tropical countries. We report here 11 cases of delineated intestinal microsporidioses due to E. hellem diagnosed in France in non-HIV patients. Briefly, all patients were immunocompromised. They all suffered from diarrhoea, associated in nearly 50% of cases with weight loss. Concerning treatment, 5/11 patients had a discontinuation or a decrease of their immunosuppressive therapy, and 4/11 received albendazole. All patients recovered. Five different genotypes were identified based on the rRNA ITS sequence.


Subject(s)
Encephalitozoon , Enterocytozoon , Microsporidiosis , Humans , Encephalitozoon/genetics , Enterocytozoon/genetics , Intestines , Feces
5.
Clin Microbiol Infect ; 29(5): 652.e9-652.e15, 2023 May.
Article in English | MEDLINE | ID: mdl-36509375

ABSTRACT

OBJECTIVES: To determine the epidemiological cut-off values (ECVs) of ten antifungal agents in a wide range of yeasts and Aspergillus spp. using gradient concentration strips. METHODS: The minimum inhibitory concentrations for amphotericin B, anidulafungin, caspofungin, micafungin, flucytosine, fluconazole, itraconazole, isavuconazole, posaconazole, and voriconazole, determined with gradient concentration strips at 35 French microbiology laboratories between 2002 and 2020, were retrospectively collected. Then, the ECVs were calculated using the iterative method and a cut-off value of 97.5%. RESULTS: Minimum inhibitory concentrations were available for 17 653 clinical isolates. In total, 48 ECVs (including 32 new ECVs) were determined: 29 ECVs for frequent yeast species (e.g. Candida albicans and itraconazole/flucytosine, and Candida glabrata species complex [SC] and flucytosine) and rare yeast species (e.g. Candida dubliniensis, Candida inconspicua, Saccharomyces cerevisiae, and Cryptococcus neoformans) and 19 ECVs for Aspergillusflavus SC, Aspergillusfumigatus SC, Aspergillusnidulans SC, Aspergillusniger SC, and Aspergillusterreus SC. CONCLUSIONS: These ECVs can be added to the already available gradient concentration strip-specific ECVs to facilitate minimum inhibitory concentration interpretation and streamline the identification of nonwild type isolates.


Subject(s)
Antifungal Agents , Itraconazole , Humans , Antifungal Agents/pharmacology , Itraconazole/pharmacology , Flucytosine , Saccharomyces cerevisiae , Retrospective Studies , Phylogeny , Fluconazole/pharmacology , Aspergillus , Microbial Sensitivity Tests , Drug Resistance, Fungal
6.
PLoS Negl Trop Dis ; 16(8): e0010691, 2022 08.
Article in English | MEDLINE | ID: mdl-35939518

ABSTRACT

BACKGROUND: Cases of Toxoplasma reactivation or more severe primary infection have been reported in patients receiving immunosuppressive (IS) treatment for autoimmune diseases (AID). The purpose of this study was to describe features of toxoplasmosis occurring in patients with AID treated by IS therapy, excluded HIV-positive and transplant patients. METHODS: A multicenter descriptive study was conducted using data from the French National Reference Center for Toxoplasmosis (NRCT) that received DNA extracts or strains isolated from patients, associated with clinical data. Other cases were retrieved through a questionnaire sent to all French parasitology and internal medicine departments. Furthermore, a systematic literature review was conducted. RESULTS: 61 cases were collected: 25 retrieved by the NRCT and by a call for observations and 36 from a literature review. Half of the cases were attributed to reactivation (50.9%), and most of cases (49.2%) were cerebral toxoplasmosis. The most common associated AID were rheumatoid arthritis (28%) and most frequent treatments were antimetabolites (44.3%). Corticosteroids were involved in 60.7% of cases. Patients had a favorable outcome (50.8%) but nine did not survive. For 12 cases, a successful Toxoplasma strain characterization suggested the possible role of this parasitic factor in ocular cases. CONCLUSION: Although this remains a rare condition, clinicians should be aware for the management of patients and for the choice of IS treatment.


Subject(s)
Autoimmune Diseases , Toxoplasma , Toxoplasmosis, Cerebral , Adrenal Cortex Hormones , Autoimmune Diseases/complications , Autoimmune Diseases/drug therapy , Humans , Immunosuppressive Agents/adverse effects , Multicenter Studies as Topic , Toxoplasma/genetics
7.
Pathogens ; 11(6)2022 Jun 17.
Article in English | MEDLINE | ID: mdl-35745553

ABSTRACT

Cryptococcosis is the third most common cause of invasive fungal infection in solid organ transplant recipients and cryptococcal meningitis (CM) its main clinical presentation. CM outcomes, as well as its clinical features and radiological characteristics, have not yet been considered on a large scale in the context of kidney transplantation (KT). We performed a nationwide retrospective study of adult patients diagnosed with cryptococcosis after KT between 2002 and 2020 across 30 clinical centers in France. We sought to describe overall and graft survival based on whether KT patients with cryptococcosis developed CM or not. Clinical indicators of CNS involvement and brain radiological characteristics were assessed. Eighty-eight cases of cryptococcosis were diagnosed during the study period, with 61 (69.3%) cases of CM. Mortality was high (32.8%) at 12 months (M12) but not significantly different whether or not patients presented with CM. Baseline hyponatremia and at least one neurological symptom were independently associated with CM (p < 0.001). Positive serum cryptococcal antigen at diagnosis was also significantly associated with CM (p < 0.001). On magnetic resonance imaging (MRI), three patterns of brain injury were identified: parenchymal, meningeal, and vascular lesions. Although CM does not affect graft function directly, it entails a grim prognosis.

8.
Med Mycol ; 60(4)2022 Apr 29.
Article in English | MEDLINE | ID: mdl-35404411

ABSTRACT

Although Candida spp are aerobic microorganisms, some Candida strains, mainly Candida glabrata, can be recovered from anaerobic blood culture vials. We assessed the contribution of the anaerobic vials for the diagnosis of candidemia, especially for C. glabrata. We conducted a multicenter retrospective study including eight university or regional hospitals. A single episode of monomicrobial candidemia per patient was included from September 1st, 2016, to August 31st, 2019. The characteristics of all aerobic and anaerobic blood culture vials sampled within 2 h before and after the first positive blood culture vials were recorded (type of vials, result, and for positive vials time-to-positivity and Candida species). Overall, 509 episodes of candidemia were included. The main species were C. albicans (55.6%) followed by C. glabrata (17.1%), C. parapsilosis (4.9%), and C. tropicalis (4.5%). An anaerobic vial was positive in 76 (14.9%) of all episodes of which 56 (73.8%) were due to C. glabrata. The number of C. glabrata infections only positive in anaerobic vials was 1 (2.6%), 1 (11.1%), and 15 (37.5%) with the BACT/ALERT 3D the BACT/ALERT VIRTUO and the BACTEC FX instrument, respectively (P < 0.01). The initial positivity of an anaerobic vial was highly predictive of the isolation of C. glabrata with the BACTEC FX (sensitivity of 96.8%). C. glabrata time-to-positivity was shorter in anaerobic vial than aerobic vial with all instruments. Anaerobic blood culture vials improve the recovery of Candida spp mainly C. glabrata. This study could be completed by further analyses including mycological and pediatric vials. LAY SUMMARY: Although Candida spp are aerobic microorganisms, C. glabrata is able to grow in anaerobic conditions. In blood culture, the time-to-positivity of C. glabrata is shorter in anaerobic than aerobic vials. Only the anaerobic vial was positive in up to 15 (37.5%) C. glabrata bloodstream infections.


Subject(s)
Candidemia , Anaerobiosis , Animals , Blood Culture/veterinary , Candida , Candida albicans , Candida glabrata , Candidemia/diagnosis , Candidemia/veterinary , Humans , Retrospective Studies
9.
Rev Prat ; 72(10): 1133-1129, 2022 Dec.
Article in French | MEDLINE | ID: mdl-36891802

ABSTRACT

First malaria vaccine recommended by who. RST,S/AS01, the first WHO recommended vaccine against malaria, is the result of decades of research. It is a recombinant protein vaccine which induces a protection against Plasmodium falciparum malaria, mediated by both humoral, and cell mediated immune responses to the circumsporozoite protein. RST,S/AS01 is of moderate efficacy against malaria, but is an additional tool for malaria control and elimination. More effective vaccines against malaria are expected within the next decades. The WHO recommendation made in October 2021, of its widespread use in children in malaria-endemic areas has raised hopes but also concerns. The timeline of the adoption by most countries of moderate to high malaria transmission, of RST,S/AS01 in the small children vaccine schedule, is still unknown.


Un premier vaccin contre le paludisme recommandé par l'OMS. Le premier vaccin recommandé par l'OMS contre le paludisme, RST,S/AS01, est le fruit de plusieurs décennies de recherche. Il s'agit d'un vaccin à protéine recombinante qui protège contre le paludisme à Plasmodium falciparum grâce à une immunité à médiations humorale et cellulaire dirigées contre la protéine circumsporozoïte. Son efficacité reste modeste, mais il constitue un outil supplémentaire dans la lutte contre le paludisme. Des vaccins plus efficaces sont attendus dans les prochaines décennies. La recommandation par l'OMS en octobre 2021 de l'utiliser à grande échelle chez les enfants en zone endémique du paludisme suscite des espoirs mais aussi des interrogations. Le calendrier d'inclusion de RST,S/AS01 dans les programmes nationaux de vaccination des jeunes enfants de la plupart des pays de transmission modérée à élevée du paludisme est encore inconnu.


Subject(s)
Malaria Vaccines , Malaria, Falciparum , Malaria , Child , Humans , Malaria Vaccines/therapeutic use , Plasmodium falciparum , Malaria, Falciparum/prevention & control , Malaria/prevention & control , World Health Organization
10.
Virulence ; 12(1): 818-834, 2021 12.
Article in English | MEDLINE | ID: mdl-33682618

ABSTRACT

The invertebrate Galleria mellonella has increasingly and widely been used in the last few years to study complex host-microbe interactions. Aspergillus fumigatus is one of the most pathogenic fungi causing life-threatening diseases in humans and animals. Galleria mellonella larvae has been proven as a reliable model for the analysis of pathogenesis and virulence factors, enable to screen a large number of A. fumigatus strains. This review describes the different uses of G. mellonella to study A. fumigatus and provides a comparison of the different protocols to trace fungal pathogenicity. The review also includes a summary of the diverse mutants tested in G. mellonella, and their respective contribution to A. fumigatus virulence. Previous investigations indicated that G. mellonella should be considered as an interesting tool even though a mammalian model may be required to complete and verify initial data.


Subject(s)
Aspergillosis/microbiology , Aspergillus fumigatus/pathogenicity , Larva/microbiology , Moths/microbiology , Virulence Factors/analysis , Animals , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillus fumigatus/drug effects , Disease Models, Animal , Drug Resistance, Fungal , Host-Pathogen Interactions , Virulence
12.
Parasitol Int ; 79: 102165, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32589941

ABSTRACT

BACKGROUND: We report a case of fatal congenital toxoplasmosis with maternal infection dated four months before pregnancy in the absence of any specific immunosuppressive condition. CASE: Ms. D. experienced submaxillary lymphadenitis in February 2018. The medical workup performed revealed an acute T. gondii infection. She became pregnant in June 2018 while she still had adenopathy. The second obstetrical ultrasound, performed at 16 weeks of pregnancy, revealed a fetal death. The research for T. gondii by PCR was positive in the products of conception. CONCLUSION: Diagnosis of toxoplasmosis should be discussed in case of miscarriage with lymphadenitis. As lymph nodes in T. gondii infection could be responsible for iterative release of parasites and fetal death, symptomatic toxoplasmosis should be treated in women of childbearing age.


Subject(s)
Abortion, Spontaneous/parasitology , Pregnancy Complications, Parasitic/diagnosis , Toxoplasmosis, Congenital/diagnosis , Adult , Fatal Outcome , Female , Humans , Infectious Disease Transmission, Vertical , Pregnancy , Pregnancy Complications, Parasitic/parasitology , Toxoplasmosis, Congenital/complications , Toxoplasmosis, Congenital/parasitology
13.
Rev Prat ; 69(10): 1113-1117, 2019 Dec.
Article in French | MEDLINE | ID: mdl-32237586

ABSTRACT

TRAVELLER'S DIARRHEA. Despite the global economic development and improvement of infrastructures in the context of mass tourism, diarrhea remains one of the most common health problems encountered by travelers. Majority of these diarrheas are selflimiting but can lead to seeking primary medical care. Two clinical entities can be distinguished: acute diarrhea and persistent diarrhea, resulting in most cases respectively from an infectious bacterial and parasitic origin. The clinician must keep in mind the signs that can lead to immediate or delayed complications and be aware of emergency situations. This article presents the main etiologies and their management, along with the health education messages to deliver in order to prevent risky situations.


DIARRHÉE DU VOYAGEUR. Malgré le développement économique mondial et l'amélioration des infrastructures liées au tourisme de masse, la diarrhée reste un des problèmes de santé les plus fréquemment rencontrés par les voyageurs. La majorité de ces diarrhées sont spontanément résolutives, mais peuvent conduire à des recours aux soins. Deux entités cliniques sont distinguables : les diarrhées aiguës et les diarrhées persistantes, résultant dans la plupart des cas respectivement d'une origine infectieuse bactérienne et parasitaire. Si elles sont majoritairement bénignes, le clinicien doit être attentif aux signes pouvant déboucher sur des complications immédiates ou différées, et ne pas méconnaître certaines situations d'urgence. Cet article reprend les principales causes et leur prise en charge, ainsi que les messages d'éducation sanitaire à enseigner aux voyageurs pour prévenir les situations à risque.


Subject(s)
Diarrhea , Travel , Diarrhea/diagnosis , Diarrhea/etiology , Diarrhea/therapy , Humans
14.
Front Microbiol ; 9: 2850, 2018.
Article in English | MEDLINE | ID: mdl-30542331

ABSTRACT

Introduction: Aspergillus fumigatus (Af) and Stenotrophomonas maltophilia (Sm) are pathogenic microorganisms, which coexist in the respiratory tract of cystic fibrosis (CF) patients. We recently developed an in vitro model of mixed biofilm associating Af ATCC 13073-GFP (Af13073) and Sm ATCC 13637 (Sm13637) and described an antibiosis effect. The present study aim was to assess the antibiosis of Sm on Af using different strains and to analyze the potential synergistic virulence of these strains in an in vivo Galleria mellonella model. Methods: The effect of Sm13637 was evaluated on eight Af strains and the effect of nine Sm strains was evaluated on Af13073. The strains originated from clinical cases (human and animal) and from environment. Fungal and bacterial inocula were simultaneously inoculated to initiate mixed biofilm formation. Fungal growth inhibition was analyzed by qPCR and CLSM and the fungal cell wall modifications by TEM analysis. The virulence of different Sm strains was assessed in association with Af in G. mellonella larvae. Results: All strains of Af and Sm were able to produce single and mixed biofilms. The antibiosis effect of Sm13637 was similar whatever the Af strain tested. On the other hand, the antibiosis effect of Sm strains was bacterial-fitness and strain dependent. One strain (1/9) originated from animal clinical case was never able to induce an antibiosis, even with high bacterial concentration. In the G. mellonella model, co-inoculation with Sm13637 and Af13073 showed synergism since the mortality was 50%, i.e., more than the summed virulence of both. Conclusion: Human clinical strains of Sm yielded in higher antibiosis effect on Af and in a thinner mixed biofilm, probably due to an adaptive effect of these strains. Further research covering Af increased wall thickness in the presence of Sm strains, and its correlation with modified antifungal susceptibility is encouraged in patients with chronic respiratory infections by these 2 microorganisms.

15.
Trends Parasitol ; 34(2): 140-154, 2018 02.
Article in English | MEDLINE | ID: mdl-29174610

ABSTRACT

Exploring the genetic diversity of Toxoplasma gondii is essential for an understanding of its worldwide distribution and the determinants of its evolution. Africa remains one of the least studied areas of the world regarding T. gondii genetic diversity. This review has compiled published data on T. gondii strains from Africa to generate a comprehensive map of their continent-wide geographical distribution. The emerging picture about T. gondii strain distribution in Africa suggests a geographical separation of the parasite populations across the continent. We discuss the potential role of a number of factors in shaping this structure. We finally suggest the next steps towards a better understanding of Toxoplasma epidemiology in Africa in light of the strains circulating on this continent.


Subject(s)
Genetic Variation , Toxoplasma/genetics , Africa/epidemiology , Animals , Demography , Toxoplasma/classification , Toxoplasmosis/epidemiology , Toxoplasmosis/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...